STERIS plc (STE) — Fair Value Analysis

Base-case fair value (P50): $193.38 · Current price: $212.11 · Verdict: Fairly Valued

The Verdict on STE

Steris (STE) is currently assessed as Fairly Valued based on our latest Monte Carlo simulations. The current trading price of $207.45 sits just above our calculated median fair value (P50) of $191.84. This represents a modest -7.5% difference from the current market price, suggesting the stock is trading close to its intrinsic worth. Despite the slight premium to the median estimate, the overall analysis indicates a balanced valuation within the Healthcare sector.

How STE stacks up against Healthcare

Steris's operational and financial health is currently categorized as an "average" quality tier when compared to its peers within the Healthcare sector. This average standing influences the fair value derivation, as it reflects the company's consistent, but not exceptional, performance relative to broader industry benchmarks. The Monte Carlo simulations incorporate this quality assessment, providing a fair value estimate that aligns with STE's established financial profile in the competitive Healthcare landscape. The $191.84 P50 fair value is a direct output of these simulations, considering STE's specific attributes against sector-wide dynamics.

What this means for investors

For investors considering STE at its current price of $207.45, the fair value assessment of Fairly Valued suggests that the market is largely reflecting the company's fundamentals. While the median fair value of $191.84 indicates a slight theoretical downside from the current price, the -7.5% gap is within a typical range for a fairly valued stock. Investors seeking a deeper understanding of potential upside or downside scenarios would benefit from exploring the full distribution of Monte Carlo outcomes. With FairCurve, you can sign up for free to access the complete bear and bull case distributions and track STE's fair value as new fundamentals are released.